-
-
-
-
-
-
-
Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)
-
-
-
-
-
-
-
RBC Capital on Acadia Pharmaceuticals (ACAD): 'Setup Skews Net Favorably'
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citizens: Potential for Robust Growth
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
-
-
-
-
-
-
Needham Names MindMed (MNMD) New Top Pick for 2026, Adds to Conviction List
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $32 at RBC Capital
-
-
-
-
-
-
-
BMO Capital Cuts Acadia Pharmaceuticals (ACAD) Stock PT Following ACP-101 Miss
-
427,981 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

